| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12094-010-0501-0 |
| P698 | PubMed publication ID | 20462834 |
| P2093 | author name string | A Rovira | |
| F Rojo | |||
| I Cañadas | |||
| J Albanell | |||
| E Arriola | |||
| M Arumí-Uría | |||
| P2860 | cites work | Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas | Q73586595 |
| Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? | Q73787127 | ||
| Interactions between scatter factors and their receptors: hints for therapeutic applications | Q77373979 | ||
| Clinical significance of c-met oncogene alterations in human colorectal cancer | Q77796048 | ||
| Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas | Q77931840 | ||
| Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor | Q24294589 | ||
| Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | Q24541450 | ||
| Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity | Q24546366 | ||
| An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice | Q24561588 | ||
| Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor | Q24564783 | ||
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 | ||
| Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. | Q27635335 | ||
| SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo | Q27658318 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics | Q28181973 | ||
| A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo | Q28183526 | ||
| HGF/SF-met signaling in the control of branching morphogenesis and invasion | Q28202466 | ||
| Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein | Q28210330 | ||
| K252a inhibits the oncogenic properties of Met, the HGF receptor | Q28214703 | ||
| Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B | Q28216726 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Invasive growth: a MET-driven genetic programme for cancer and stem cells | Q28253680 | ||
| The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants | Q28254690 | ||
| The Met tyrosine kinase receptor in development and cancer | Q28263626 | ||
| A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo | Q28270305 | ||
| Targeting the tumor and its microenvironment by a dual-function decoy Met receptor | Q28272715 | ||
| Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase | Q28286701 | ||
| Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development | Q28295203 | ||
| Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma | Q30014823 | ||
| XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. | Q30428632 | ||
| The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma | Q30494514 | ||
| Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. | Q33687878 | ||
| Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene | Q33696499 | ||
| Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding | Q33938013 | ||
| Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation | Q34097397 | ||
| A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase | Q34263863 | ||
| Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement | Q34294357 | ||
| c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention | Q34422211 | ||
| Dysregulation of Met receptor tyrosine kinase activity in invasive tumors | Q34584046 | ||
| An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 | ||
| Scatter-factor and semaphorin receptors: cell signalling for invasive growth | Q34632043 | ||
| Drug development of MET inhibitors: targeting oncogene addiction and expedience | Q34782774 | ||
| c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases | Q35199181 | ||
| Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation | Q35277738 | ||
| Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma | Q35773856 | ||
| Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients | Q35926926 | ||
| Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. | Q36136355 | ||
| Cancer therapy: can the challenge be MET? | Q36159458 | ||
| Activating mutations for the met tyrosine kinase receptor in human cancer | Q36595980 | ||
| c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays | Q36609706 | ||
| Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. | Q36689648 | ||
| c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy | Q36731520 | ||
| The MET receptor tyrosine kinase in invasion and metastasis | Q36868644 | ||
| Met and hepatocyte growth factor/scatter factor expression in human gliomas | Q36894692 | ||
| The shadow of death on the MET tyrosine kinase receptor | Q36961606 | ||
| NK4 gene therapy targeting HGF-Met and angiogenesis. | Q36992304 | ||
| Molecular cancer therapy: can our expectation be MET? | Q37092832 | ||
| FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors | Q37208761 | ||
| MET as a target for treatment of chest tumors | Q37232416 | ||
| Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors | Q37356573 | ||
| Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair | Q37357884 | ||
| Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures | Q37397472 | ||
| Novel therapeutic inhibitors of the c-Met signaling pathway in cancer | Q37422804 | ||
| The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions | Q37525133 | ||
| Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele | Q37705080 | ||
| Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript | Q38332144 | ||
| Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization | Q38449042 | ||
| Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx | Q38450015 | ||
| The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells | Q39760115 | ||
| AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts | Q40050768 | ||
| A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts | Q40144642 | ||
| c-Met is a potentially new therapeutic target for treatment of human melanoma | Q40150516 | ||
| Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts | Q40314133 | ||
| Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma | Q40333091 | ||
| Somatic mutations lead to an oncogenic deletion of met in lung cancer | Q40333112 | ||
| Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. | Q40453775 | ||
| c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions | Q40626106 | ||
| A novel germ line juxtamembrane Met mutation in human gastric cancer | Q40847293 | ||
| Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis | Q41038360 | ||
| Overexpression of the met/HGF receptor in renal cell carcinomas | Q41190769 | ||
| Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype | Q42508648 | ||
| Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. | Q42802665 | ||
| Scatter factor is a fibroblast-derived modulator of epithelial cell mobility | Q42807925 | ||
| Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists | Q42810535 | ||
| Coupling Met to specific pathways results in distinct developmental outcomes | Q43656791 | ||
| Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. | Q44235704 | ||
| Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors | Q44389290 | ||
| Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 | ||
| Molecular cloning of a new transforming gene from a chemically transformed human cell line. | Q45345810 | ||
| The Sema domain of Met is necessary for receptor dimerization and activation | Q46131945 | ||
| c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. | Q46265281 | ||
| Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers | Q47706538 | ||
| Overexpression of the Met/HGF receptor in ovarian cancer. | Q48079353 | ||
| High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. | Q51787351 | ||
| Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. | Q53778646 | ||
| Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. | Q55284672 | ||
| c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion | Q64377234 | ||
| Gene amplification in gastric and esophageal adenocarcinomas | Q68920865 | ||
| Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas | Q71061803 | ||
| Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers | Q71478326 | ||
| Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF | Q72403509 | ||
| The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit | Q72560868 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 253-260 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Clinical and Translational Oncology | Q15754324 |
| P1476 | title | C-MET as a new therapeutic target for the development of novel anticancer drugs | |
| P478 | volume | 12 |
| Q47164810 | A novel G-quadruplex motif in the Human MET promoter region |
| Q35832903 | Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach |
| Q28262538 | Antibody therapy of cancer |
| Q34080493 | Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay |
| Q24608143 | Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197 |
| Q51438298 | Exploring c-Met kinase flexibility by sampling and clustering its conformational space. |
| Q36103429 | Head and neck squamous cell carcinoma in pregnant women |
| Q39608945 | Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis |
| Q36547939 | Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer |
| Q51610986 | Identification of Inhibitors of the Tyrosine Kinase c-Met by Structure-Based Virtual Screening. |
| Q39395884 | Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity |
| Q38956316 | MET overexpression and gene amplification in NSCLC: a clinical perspective. |
| Q38087239 | Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications |
| Q84808389 | Monoclonal antibodies in cancer therapy |
| Q64238086 | Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma |
| Q90590609 | Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α |
| Q54540287 | Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors. |
| Q38009760 | Targeted therapy for triple-negative breast cancer: where are we? |
| Q24606259 | Targeting the hepatocyte growth factor-cMET axis in cancer therapy |
| Q35740444 | The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy |
| Q43819146 | The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme |
| Q37059865 | Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck |
| Q38545050 | USP8: a novel therapeutic target for Cushing's disease. |
Search more.